Researchers testing new brain cancer vaccine

September 13, 2018, Rush University Medical Center
Glioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0

Rush University Medical Center is part of a new clinical trial testing whether an experimental vaccine can help patients' immune systems stop the spread of glioblastoma—an aggressive form of brain cancer with very few current treatment options.

Led by neuro-oncologist Clement Pillainayagam, MD, the phase II clinical trial is testing an investigational vaccine that will be given in conjunction with bevacizumab, an FDA-approved drug that targets the proteins need to grow . Rush is one of only a few Midwest locations for this international trial, Drug Treatment Study for Recurrent or Progressive Glioblastoma.

Glioblastomas are malignant tumors that begin in the glial, or supportive, tissue of the brain and spread rapidly because they are supported by a large network of blood vessels. There is no known cure for tumors, and median survival is just four months without treatment and 15 to 19 months with treatment. In a stark reminder of the need for better treatments, U.S. Sen. John McCain died from glioblastoma on Aug. 25, one of more than 15,000 people in the United States who succumb to each year, according to the National Cancer Institute.

Current standard treatments typically involve surgery followed by chemotherapy and radiation therapy. Immunotherapies like those being tested in this trial, which engage the body's immune system to attack tumors, increasingly are becoming part of treatment plans.

"Our immune system would typically put a stop to growing, but glioblastoma cells suppress this process." Pillainayagam explains.

"Bevacizumab has been shown to help the immune system starve tumors of their blood supply as well as decrease the immunosuppressed state around the tumor. But that just isn't enough," he said.

Starving the tumor and revving up the immune system

Half of the study participants chosen at random will receive bevacizumab, and the other half will be treated with bevacizumab plus the . The vaccine (DSP-788-201G) is derived from peptides (short chains of amino acids) produced by the WT1gene that is found in many types of cancer cells, including glioblastomas.

The vaccine is used by the HLA (human leukocyte antigen) system, cell surface proteins that help regulate the immune system. "While the bevacizumab helps starve the tumor by blocking formation of blood vessels inside it, we hope the vaccine revs up the immune response by helping the body recognize that these cancer cells are a threat," Pillainayagam said.

Though the development in recent years of therapies that help people's own target cancer cells has meant new options for many types of cancers, very few immunotherapies for cancers in the brain have shown promise. "The brain has different types of that work in unique combinations. Thus, trying to understand how to unleash our own immune systems is a challenge," Pillainayagam says.

One challenge is actually a barrier: The human body evolved a layer of specialized cells, called the blood-brain barrier, that line the blood vessels in the brain, providing extra security from threats such as viruses and bacteria that circulate in the rest of the bloodstream. That extra layer of protection also prevents many cancer-fighting drugs from working. By some estimates, 98 percent of current FDA-approved drugs do not enter the brain because of the blood-brain barrier.

Brain cancers affect what make people who they are

Along with Joo Yeon Nam, MD, Pillainayagam leads Rush's Section of Neuro-oncology, which works in conjunction with specialists across Rush's Department of Neurological Sciences to treat patients with primary cancers of the brain and spine.

"The brain is sensitive and exquisite real estate. Everything we do and even who we are depends on the brain functioning well, thus even a tiny growth can have an enormous impact" Pillainayagam says.

He adds that dual training in oncology and neurology usually comes into play several times during a single appointment. "As an oncologist, my focus is typically at the cellular level, focusing on the chemotherapy, radiation and other tools that keep cells in check. But as a neurologist, I am addressing the neurological impact the cancers have on people's movements, thinking and even personality."

Nam says that the dual training in oncology and neurology is especially necessary because brain cancers have such deep impact on the quality of life of patients and their families. In addition to causing neurological problems such as weakness, seizures and impaired speech, " cancers like glioblastomas affect the part of the body that makes people who they are," she says.

Learn more about the clinical trial here or by calling (312) 942-4500.

To be eligible for this clinical trial, patients must meet the following criteria:

  • Have a diagnosis of glioblastoma
  • Have evidence of recurrence or progression of disease
  • Have recovered from effects of all prior therapies

Patients cannot participate if they have received prior bevacizumab therapy, or have received antineoplastic therapy, including radiation therapy, for first relapse or recurrence.

Explore further: Additional inhibitor can help anti-VEGF therapy overcome resistance in deadly brain cancer

Related Stories

Additional inhibitor can help anti-VEGF therapy overcome resistance in deadly brain cancer

August 27, 2018
Adding another inhibitor to therapies that cut off a tumor's access to blood vessels could be the key to helping those therapies overcome resistance in glioblastoma, a deadly form of brain cancer.

Laser therapy increases survival in grim cancer diagnosis

August 23, 2018
People diagnosed with the aggressive brain cancer glioblastoma face a grim prognosis. Half die within 14 months of diagnosis.

Brain cancer vaccine effective in some patients

May 31, 2018
Most people with the deadly brain cancer glioblastoma die less than 18 months after diagnosis. But a multicenter clinical trial of a personalized vaccine that targets the aggressive cancer has indicated improved survival ...

Experimental drug combined with radiation kills brain tumors in pre-clinical studies

June 27, 2018
A new study led by scientists at VCU Massey Cancer Center has shown that an experimental drug known as AZ32 selectively sensitizes brain tumors to radiation and significantly extends the survival of mouse models with human ...

Clinical trial evaluating brain cancer vaccine is underway

October 19, 2007
A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center. The study will evaluate the addition of the vaccine following standard therapy with surgery ...

Combination therapy for glioblastoma shows promising results in early-stage research

January 25, 2017
UCLA researchers have discovered that combining a vaccine developed at UCLA with other experimental therapies and FDA-approved treatments shows promise for reducing the size of advanced brain tumors. The immunotherapy, which ...

Recommended for you

Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse

September 24, 2018
Harnessing the immune system to treat cancer shows great promise in some patients, but for many, the response does not last long-term. In an effort to find out why, Fred Hutchinson Cancer Research Center scientists are using ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.